BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 24356886)

  • 1. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes.
    Chowdhury S; Reeds DN; Crimmins DL; Patterson BW; Laciny E; Wang S; Tran HD; Griest TA; Rometo DA; Dunai J; Wallendorf MJ; Ladenson JH; Polonsky KS; Wice BM
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G301-9. PubMed ID: 24356886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal Responses to Cholinergic Input Are Different in Humans with and without Type 2 Diabetes Mellitus.
    Chowdhury S; Wang S; Dunai J; Kilpatrick R; Oestricker LZ; Wallendorf MJ; Patterson BW; Reeds DN; Wice BM
    PLoS One; 2016; 11(6):e0156852. PubMed ID: 27304975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of GIP plus xenin-25 indirectly increases pancreatic polypeptide release in humans with and without type 2 diabetes mellitus.
    Chowdhury S; Wang S; Patterson BW; Reeds DN; Wice BM
    Regul Pept; 2013 Nov; 187():42-50. PubMed ID: 24183983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic responses to xenin-25 are altered in humans with Roux-en-Y gastric bypass surgery.
    Sterl K; Wang S; Oestricker L; Wallendorf MJ; Patterson BW; Reeds DN; Wice BM
    Peptides; 2016 Aug; 82():76-84. PubMed ID: 27288245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance.
    Wang S; Oestricker LZ; Wallendorf MJ; Sterl K; Dunai J; Kilpatrick CR; Patterson BW; Reeds DN; Wice BM
    PLoS One; 2018; 13(2):e0192441. PubMed ID: 29466430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
    Meier JJ; Kemmeries G; Holst JJ; Nauck MA
    Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes.
    Wice BM; Reeds DN; Tran HD; Crimmins DL; Patterson BW; Dunai J; Wallendorf MJ; Ladenson JH; Villareal DT; Polonsky KS
    Diabetes; 2012 Jul; 61(7):1793-800. PubMed ID: 22522617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes.
    Alsalim W; Tura A; Pacini G; Omar B; Bizzotto R; Mari A; Ahrén B
    Diabetes Obes Metab; 2016 Jan; 18(1):24-33. PubMed ID: 26354383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.
    Ruetten H; Gebauer M; Raymond RH; Calle RA; Cobelli C; Ghosh A; Robertson RP; Shankar SS; Staten MA; Stefanovski D; Vella A; Wright K; Fryburg DA;
    Metab Syndr Relat Disord; 2018 Oct; 16(8):406-415. PubMed ID: 30117761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.
    Kielgast U; Holst JJ; Madsbad S
    Diabetes; 2011 May; 60(5):1599-607. PubMed ID: 21441444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.
    Kuwata H; Iwasaki M; Shimizu S; Minami K; Maeda H; Seino S; Nakada K; Nosaka C; Murotani K; Kurose T; Seino Y; Yabe D
    Diabetologia; 2016 Mar; 59(3):453-61. PubMed ID: 26704625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.
    Sonne DP; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    Eur J Endocrinol; 2014 Oct; 171(4):407-19. PubMed ID: 24986531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
    J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Postprandial Glycaemic and Hormonal Responses Following the Ingestion of a Novel, Ready-to-Drink Shot Containing a Low Dose of Whey Protein in Centrally Obese and Lean Adult Males: A Randomised Controlled Trial.
    Smith K; Taylor GS; Allerton DM; Brunsgaard LH; Bowden Davies KA; Stevenson EJ; West DJ
    Front Endocrinol (Lausanne); 2021; 12():696977. PubMed ID: 34220720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
    Wu T; Little TJ; Bound MJ; Borg M; Zhang X; Deacon CF; Horowitz M; Jones KL; Rayner CK
    Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
    Gasbjerg LS; Helsted MM; Hartmann B; Jensen MH; Gabe MBN; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    Diabetes; 2019 May; 68(5):906-917. PubMed ID: 30626611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intragastric administration of the bitter tastant quinine lowers the glycemic response to a nutrient drink without slowing gastric emptying in healthy men.
    Bitarafan V; Fitzgerald PCE; Little TJ; Meyerhof W; Jones KL; Wu T; Horowitz M; Feinle-Bisset C
    Am J Physiol Regul Integr Comp Physiol; 2020 Feb; 318(2):R263-R273. PubMed ID: 31774306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.